Daniel O'Day

Gilead to Buy Cancer Drugmaker for $21 Billion
M&A

Gilead to Buy Cancer Drugmaker for $21 Billion

The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
By Matthew Heller | September 14, 2020
Read More
Gilead to Invest $5B in Galapagos Partnership
Strategy

Gilead to Invest $5B in Galapagos Partnership

The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
By Matthew Heller | July 15, 2019
Read More
Roche Buys Flatiron in $1.9B ‘Big Data’ Move
Technology

Roche Buys Flatiron in $1.9B ‘Big Data’ Move

The real-world evidence Flatiron's record system collects "is a key ingredient to accelerate the development of, and access to, new cancer treatments."
By Matthew Heller | February 15, 2018
Read More